SCHEMBL20041727

SCHEMBL20041727

O=C(O)c1nonc1NCc1ccccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOA P21397 1/20 0.50
MAOB P27338 1/20 0.50
SMN1; SMN2 Q16637 4/20 0.49
CSNK2A1 P68400 1/20 0.47
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
HDAC6 Q9UBN7 1/20 0.46
RAB9A P51151 4/20 0.46
NPC1 O15118 3/20 0.46
POLB P06746 2/20 0.46
STAT5B P51692 2/20 0.46
KMT2A Q03164 2/20 0.45
MAPK1 P28482 1/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
AURKA O14965 1/20 0.44
RPS6KB1 P23443 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20041728 0.77 MAOA (0.51) MAOAMAOBSMN1; SMN2RAB9ANPC1
SCHEMBL1467625 0.75 MAOA (0.54) MAOAMAOBSMN1; SMN2HDAC3HDAC1
SCHEMBL18394876 0.71 MAOA (0.56) MAOAMAOBSMN1; SMN2HDAC3HDAC1
SCHEMBL29664470 0.71 MAOA (0.56) MAOAMAOBSMN1; SMN2HDAC3HDAC1
SCHEMBL2635637 0.71 MAOA (0.70) MAOAMAOBSMN1; SMN2CSNK2A1HDAC3
SCHEMBL3332845 0.70 SORT1 (0.48) MAOAMAOBSMN1; SMN2CSNK2A1HDAC3
SCHEMBL8690909 0.69 MAOA (0.50) MAOAMAOBSMN1; SMN2CSNK2A1HDAC3
SCHEMBL2825966 0.69 SMN1; SMN2 (0.49) MAOAMAOBSMN1; SMN2CSNK2A1RAB9A
SCHEMBL243740 0.69 SMN1; SMN2 (0.76) SMN1; SMN2RAB9ANPC1POLBKMT2A
SCHEMBL30602600 0.69 SMN1; SMN2 (0.76) SMN1; SMN2RAB9ANPC1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3523297-B1 NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER UNIV BERLIN FREIE (DE) 2021-07-07 EP disclosed
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FREIE UNIVERSITAET BERLIN (DE) 2020-06-16 US disclosed
WO-2018065536-A1 NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER FREIE UNIVERSITÄT BERLIN (DE) 2018-04-12 WO disclosed
EP-3305783-A1 NOVEL FURAZAN-3-CARBOXYLIC ACID DERIVATIVES AND USE THEREOF IN TREATMENT OF CANCER Freie Universität Berlin (DE) 2018-04-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10683286-B2 Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer FLT3, MCL1, MYD88 MAOA 2761/4885MAOB 3039/4885SMN1; SMN2 3053/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.